Jennifer Mcneer
Expertise in
2
conditions

Dr. Jennifer Mcneer

Pediatrics
100 N Mario Capecchi Dr, 
Salt Lake City, UT 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Referral required
Expertise in
2
conditions
100 N Mario Capecchi Dr, 
Salt Lake City, UT 

Overview

Jennifer Mcneer is a Pediatrics provider practicing medicine in Salt Lake City, Utah.

Dr. Mcneer is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Febrile Neutropenia, Infantile Neutropenia, and Bone Marrow Aspiration.

Dr. Mcneer is board certified in American Board Of Pediatrics. She is actively involved in clinical research, co-authoring 36 peer reviewed articles and participating in 21 clinical trials. Dr. Mcneer is currently accepting new patients.

Specialties

Pediatrics

Licenses

Pediatric Hematology-Oncology in IL

Board Certifications

American Board Of Pediatrics

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
View 2 Less Insurance Carriers -

Locations

Pediatric Hematology-oncology
100 N Mario Capecchi Dr, Salt Lake City, UT 84113
Other Locations
Pediatric Hematology-oncology - Hci
1950 Circle Of Hope Dr, Salt Lake City, UT 84112
Pediatric Hematology-oncology - University Of Utah Hospital
50 N Medical Dr, Salt Lake City, UT 84132

Additional Areas of Focus

Dr. Mcneer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: March 31, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Recruiting
Publish Date: February 23, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Inotuzumab, Leucovorin, 6-Mercaptopurine, Pegaspargase, Vincristine
Study Phase: Phase 2
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Tyrosine Kinase Inhibitor
Study Phase: Phase 2
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: February 23, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2026
Intervention Type: Other, Drug
Study Drugs: Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Mitoxantrone, Tretinoin
Study Phase: Phase 3
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: January 28, 2026
Intervention Type: Drug, Combination product, Biological
Study Drugs: Methotrexate, Hydrocortisone, Azacitidine, Decitabine, Cytarabine, Daunorubicin, Etoposide, Idarubicin, Fludarabine, Mitoxantrone, Erwinia Asparaginase, Sorafenib, Granulocyte Colony-Stimulating Factor, Dexrazoxane
Study Phase: Phase 2
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2026
Intervention Type: Genetic
Study Phase: Not Applicable
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
View 8 Less Clinical Trials

36 Total Publications

The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era.
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
Similar Doctors
Expertise in
1
conditions
Dr. Anne Moon
Pediatrics
Expertise in
1
conditions
Dr. Anne Moon
Pediatrics

Primary Children's Hospital

100 N Mario Capecchi Dr # 2, 
Salt Lake City, UT 
 (1253.0 miles away)
801-581-2121
Languages Spoken:
English

Anne Moon is a Pediatrics provider practicing medicine in Salt Lake City, Utah. Dr. Moon is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Ulnar-Mammary Syndrome.

Expertise in
11
conditions
Dr. Robert Christensen
Neonatology | Pediatrics
Expertise in
11
conditions
Dr. Robert Christensen
Neonatology | Pediatrics

Office

400 D St, 
Salt Lake City, UT 
 (1256.0 miles away)
801-408-1000
Languages Spoken:
English

Robert Christensen is a Neonatologist and a Pediatrics provider practicing medicine in Salt Lake City, Utah. Dr. Christensen is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Hemolytic Disease of the Newborn, Hemolysis, Newborn Jaundice, and Transient Familial Hyperbilirubinemia.

Expertise in
3
conditions
Dr. Harry Hill
Pediatrics
Expertise in
3
conditions
Dr. Harry Hill
Pediatrics

Office

50 N Medical Dr, 
Salt Lake City, UT 
 (1253.1 miles away)
801-581-5873
Languages Spoken:
English
See accepted insurances

Harry Hill is a Pediatrics provider practicing medicine in Salt Lake City, Utah. Dr. Hill is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Common Variable Immune Deficiency, Hyper IgE Syndrome, Autosomal Dominant Hyper IgE Syndrome, and Smoldering Multiple Myeloma.

Frequently Asked Questions about Dr. Jennifer Mcneer

How do I make an appointment with Dr. Jennifer Mcneer?

You can book an appointment with Dr. Jennifer Mcneer by calling their office at 801-662-4700. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jennifer Mcneer a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jennifer Mcneer is classified as an Distinguished expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jennifer Mcneer specialize in?

While Dr. Jennifer Mcneer is a Pediatrics, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Leukemia, and Febrile Neutropenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Jennifer Mcneer participate in research or clinical trials?

Yes. Dr. Jennifer Mcneer has published 36 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Jennifer Mcneer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jennifer Mcneer accept my insurance?

Dr. Jennifer Mcneer accepts most major insurance plans, including Aetna and BridgeSpan. We recommend calling the office directly at 801-662-4700 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcneer's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile